Literature DB >> 29484654

Ablation approach for primary liver tumors: Peri-operative outcomes.

Nicholas G Berger1, Josi L Herren1, Chrissy Liu1, Robert H Burrow1, Jack P Silva1, Susan Tsai1, Kathleen K Christians1, T Clark Gamblin1.   

Abstract

BACKGROUND AND OBJECTIVES: Ablation is a common treatment modality for malignant primary liver tumors(PLTs), outcomes following laparoscopic (LA) versus open ablation (OA) are ill-defined. This project compares peri-procedural outcomes of LA versus OA for PLTs.
MATERIALS AND METHODS: Patients with PLTs undergoing radiofrequency ablation were queried from ACS NSQIP Database (2005-2013) using CPT codes. Patients undergoing percutaneous ablation or hepatic resection were excluded. Multivariable logistic regression analyses determined the association of ablation approach with 30-day morbidity and mortality.
RESULTS: Of 5747 with PLTs, 655 (11.4%) ablations were identified: 177 (27.0%) underwent OA, 478 (73.0%) underwent LA. Patients undergoing LA had lower mortality (1.9% vs 5.1%, P = 0.026), lower minor morbidity (2.3% vs 5.7%, P = 0.031), and lower major morbidity (4.2% vs 17.0%, P < 0.001). Adjusting for demographics, disease-specific variables (preoperative ascites, total bilirubin, platelet count, albumin, and INR), 30-day mortality (OR 3.85, 95%CI: 1.38-10.80, P = 0.010), minor morbidity (OR 2.98, 95%CI: 1.16-7.67, P = 0.024), and major morbidity (OR 4.59 95%CI: 2.41-8.76, P < 0.001) were statistically lower in LA. OA demonstrated increased length of stay(LOS) (5 vs 2 days, P < 0.001), and longer operative time (152 vs 112 min, P < 0.001).
CONCLUSION: LA offers decreased peri-procedural morbidity, mortality, and reduced LOS. LA should be the preferred method for hepatic ablation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  hepatocellular carcinoma; intrahepatic cholangiocarcinoma; radiofrequency ablation

Mesh:

Year:  2018        PMID: 29484654     DOI: 10.1002/jso.25019

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  An ALBI- and Ascites-Based Model to Predict Survival for BCLC Stage B Hepatocellular Carcinoma.

Authors:  Cheng He; Jing Yang; Zheng Jin; Ying Zhu; Wei Hu; Lingfeng Zeng; Xiaocheng Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-07       Impact factor: 2.650

2.  1000 consecutive ablation sessions in the era of computer assisted image guidance - Lessons learned.

Authors:  Marie Beermann; Johan Lindeberg; Jennie Engstrand; Karolina Galmén; Silja Karlgren; David Stillström; Henrik Nilsson; Piotr Harbut; Jacob Freedman
Journal:  Eur J Radiol Open       Date:  2018-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.